logo
Share SHARE
FONT-SIZE Plus   Neg

Qiao Xing To Probe Funds Transfer By Former Chairman - Quick Facts

China-based mining company Qiao Xing Universal Resources Inc. (XING) said Friday its Audit Committee has decided to begin an internal probe into transfer of funds from the bank account of the company's unit to an account controlled by former Chairman Wu Rui Lin in June 2011.

The company said the transaction was undertaken without notice to or approval of the Audit Committee or the Board of Directors, and the transaction was recently reported to the Audit Committee in connection with the preparation of the company's year-end financial statements.

The Audit Committee has ordered immediate return of the funds. In addition, the company informed NASDAQ and the U.S. Securities and Exchange Commission of the matter under investigation.

The Audit Committee also decided to review certain transactions involving the pledge or transfer of company assets and to confirm cash balances of the company's bank accounts.

NASDAQ has suspended trading in XING's stock as of April 16, 2012.

Also, the company said that. Edward Tsai, director and chairman of the Audit Committee, has resigned as of April 18. Tsai's resignation is occasioned by his disagreement with the other directors of the company on the conduct of the internal investigation referred to above.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Sony announced Project Field, a new play way to bring card games to life, along with a host of smartphone games at an event in Japan, aiming to accelerate mobile drive. Project Field is a Japan-only card collection platform where actual physical cards will work with a smartphone app. The first title to be announced is based on Yo-kai Watch for mobile. There is no news about an international releas Shares of Credit Suisse Group AG gained around 8 percent in the morning trading in Zurich after the Swiss banking giant raised its group cost savings target, and also confirmed its medium-term 2018 pre-tax income target. It is almost the end of the year. With the exception of a few, many of the biotech stocks, like the following, on which investors had bet big this year have served up only heartbreak. Now, let's take a look at some of the pending clinical trial catalysts of this month, which will make it a December to remember.
comments powered by Disqus
Follow RTT